IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Recruitment status was: Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Biological: SCBaL/M9 | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention |
| Official Title: | Development of an Oral Prime-Boost AIDS Vaccine to Elicit Broadly Neutralizing Antibodies Against HIV-1 |
- Safety, as judged by the lack of an immune response to CD4 epitopes or other significant adverse events as defined by the HVTN toxicity tables [ Time Frame: Throughout study ]
- Neutralizing antibody response against HIV-1 [ Time Frame: Throughout study ]
| Estimated Enrollment: | 38 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
All participants will receive oral vaccine at study entry, although dosage will vary
|
Biological: SCBaL/M9
Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
|
Detailed Description:
The transmission of HIV-1 by both sexual and parenteral routes makes it likely that a successful preventive vaccine against this virus will need to induce protective immunity in both mucosal and systemic compartments. The long-term objective of this program is to develop an HIV-1 vaccine that elicits protective immunity in both the mucosal and systemic compartments.
The study will evaluate the safety and immunogenicity of an oral recombinant Salmonella typhi HIV-1 gp120 vaccine (SCBaL/M9) in healthy human volunteers. This will be the first study in volunteers to use an intracellular bacterium to deliver a recombinant vector vaccine mucosally. The study will also develop an Env immunogen that elicits a broader spectrum of neutralizing antibodies than gp120 and that can be delivered by Salmonella typhi or as a soluble protein immunogen.
This is a Phase I dose-escalation study of two vaccine components that will be combined in a larger prime-boost protocol should the desired safety endpoints be obtained. Both components use a conformationally constrained gp120 that expresses epitopes recognized by broadly neutralizing antibodies. The priming immunogen will be the conformationally constrained gp120 gene delivered orally by live attenuated Salmonella typhi. The boosting immunogen will be a soluble subunit protein comprised solely of the conformationally constrained gp120.
All participants in this study will receive the vaccine. Participants will be randomized to different vaccine doses. Participants will have eight study visits over 20 weeks. Study visits will include brief medical interview, physical exam, blood and urine tests, and counseling on avoiding HIV infection and pregnancy. Participants will be tested for HIV infection 3 times during the study.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
- HIV uninfected
- Low risk sexual behavior
- Negative for Hepatitis B surface antigen
- Negative for Hepatitis C viral sequences and antibody
- Availability for follow-up for planned duration of the study (12 months)
- Acceptable methods of contraception
Exclusion Criteria
- Receipt of HIV vaccines or placebo in a previous HIV vaccine trial
- History of immunodeficiency, chronic illness, autoimmune disease, or use of immunosuppressive medications
- History of cancer unless there has been surgical excision followed by a sufficient observation period to give a reasonable assurance of cure
- Medical or psychiatric condition or occupational responsibilities which preclude compliance with the protocol
- History of suicide attempts, recent suicidal ideation, or psychosis
- High risk behavior for HIV infection as determined by screening questionnaire
- History of injection drug use within 12 months of study entry
- Live attenuated vaccines within 60 days of study entry. Medically indicated killed or subunit vaccines (e.g., influenza, pneumococcal) are not exclusionary, but should be given at least 2 weeks away from HIV immunizations.
- Use of experimental agents within 30 days of study entry
- Receipt of blood products or immunoglobulin within 6 months of study entry
- Active syphilis
- Active tuberculosis
- History of anaphylaxis or serious adverse reactions to vaccines
- History of serious allergic reaction to any substance, requiring hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension)
- Pregnant or breastfeeding
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00062530
| Contact: George K. Lewis, PhD | 410- 706-4688 | lewisg@umbi.umd.edu |
| United States, Maryland | |
| Institute of Human Virology | Not yet recruiting |
| Baltimore, Maryland, United States, 21201 | |
| Principal Investigator: | George K. Lewis, PhD | Univesity of Maryland |
More Information
| Responsible Party: | Greg K. Lewis, PhD, University of Maryland |
| ClinicalTrials.gov Identifier: | NCT00062530 History of Changes |
| Other Study ID Numbers: |
P01AI047490 ( U.S. NIH Grant/Contract ) |
| Study First Received: | June 9, 2003 |
| Last Updated: | September 25, 2008 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
AIDS HIV seronegativity HIV preventive vaccine |
Additional relevant MeSH terms:
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral |
Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on August 18, 2017